Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARIS: Pembrolizumab + Radiotherapy in NSCLC
NCT03245177Phase 1Withdrawn
- Sponsor
- Prof Corinne Faivre-Finn
- Start
- Aug 2017
- Primary completion
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Prof Corinne Faivre-Finn. Primary endpoints: Recommended phase II dose and Dose limiting toxicity. Planned start Aug 2017; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03245177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245177.